• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

法匹拉韦诱发新型冠状病毒肺炎患者肾毒性：一例报告

Favipiravir-induced nephrotoxicity in a patient with COVID-19: A case report.

作者信息

Abdelbary Asmaa A, Alharafsheh Ahmad E, Ahmed Afif, Nashwan Abdulqadir J

机构信息

Pharmacy Department Home Health Care Services (HHCS) Hamad Medical Corporation Doha Qatar.

Pharmacy Department Hazm Mebaireek General Hospital (HMGH) Hamad Medical Corporation (HMC) Doha Qatar.

出版信息

Clin Case Rep. 2021 Aug 15;9(8):e04539. doi: 10.1002/ccr3.4539. eCollection 2021 Aug.

DOI:10.1002/ccr3.4539
PMID:34429982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8364994/
Abstract

This report describes a case of 45 years old male patient who tested positive for COVID-19 presented to the emergency department on March 2021 complaining of fever, cough, runny nose, and shortness of breath. The patient denied any history of nausea or diarrhea who has eventually developed favipiravir-induced nephrotoxicity.

摘要

本报告描述了一例45岁男性患者，该患者于2021年3月因发热、咳嗽、流鼻涕和呼吸急促前往急诊科就诊，新冠病毒检测呈阳性。患者否认有任何恶心或腹泻病史，最终出现了法匹拉韦诱导的肾毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8604/8364994/fe34ac82c99d/CCR3-9-e04539-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8604/8364994/fe34ac82c99d/CCR3-9-e04539-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8604/8364994/fe34ac82c99d/CCR3-9-e04539-g001.jpg

相似文献

1
Favipiravir-induced nephrotoxicity in a patient with COVID-19: A case report.法匹拉韦诱发新型冠状病毒肺炎患者肾毒性：一例报告
Clin Case Rep. 2021 Aug 15;9(8):e04539. doi: 10.1002/ccr3.4539. eCollection 2021 Aug.
2
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗（FLARE）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.
3
Should COVID-19 symptoms be used to cohort patients in the emergency department? A retrospective analysis.新冠病毒（COVID-19）症状是否应用于急诊科患者分组？一项回顾性分析。
Am J Emerg Med. 2022 Apr;54:274-278. doi: 10.1016/j.ajem.2022.01.070. Epub 2022 Feb 6.
4
Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.沙特阿拉伯利雅得重症监护病房 COVID-19 患者使用法维拉韦的临床转归和治疗效果概述。
J Infect Public Health. 2022 Apr;15(4):389-394. doi: 10.1016/j.jiph.2022.01.013. Epub 2022 Feb 15.
5
A 38-Year-Old Man With Persistent Fever and Progressive Shortness of Breath.一位 38 岁男性，持续发热伴进行性呼吸困难。
Chest. 2023 Nov;164(5):e131-e134. doi: 10.1016/j.chest.2023.06.031. Epub 2023 Nov 7.
6
The safety and adverse event profile of favipiravir in the treatment of COVID-19 patients, Turkey.土耳其使用法维拉韦治疗 COVID-19 患者的安全性和不良事件概况。
J Infect Dev Ctries. 2023 Nov 30;17(11):1549-1555. doi: 10.3855/jidc.18041.
7
Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection.法匹拉韦治疗合并新型冠状病毒感染的克里米亚-刚果出血热患者
Eur J Case Rep Intern Med. 2020 Dec 17;7(12):002042. doi: 10.12890/2020_002042. eCollection 2020.
8
Co-infection of COVID-19 and influenza A in a hemodialysis patient: a case report.COVID-19 与甲型流感病毒在血液透析患者中的合并感染：一例报告。
BMC Infect Dis. 2021 Jan 13;21(1):68. doi: 10.1186/s12879-020-05723-y.
9
A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.基于药物诱导的淋巴细胞刺激试验阳性，确诊为使用法匹拉韦后药物热的 COVID-19 病例。
Int J Infect Dis. 2021 May;106:33-35. doi: 10.1016/j.ijid.2021.03.048. Epub 2021 Mar 18.
10
Identification of Symptoms Prognostic of COVID-19 Severity: Multivariate Data Analysis of a Case Series in Henan Province.新冠病毒病严重程度的症状预后识别：河南省一组病例的多变量数据分析
J Med Internet Res. 2020 Jun 30;22(6):e19636. doi: 10.2196/19636.

引用本文的文献

1
Factors Contributing to Chronic Kidney Disease following COVID-19 Diagnosis in Pre-Vaccinated Hospitalized Patients.新冠疫苗接种前住院患者确诊新冠后导致慢性肾病的因素。
Vaccines (Basel). 2023 Feb 13;11(2):433. doi: 10.3390/vaccines11020433.
2
Effects of Exercise on COVID-19 Patients: A Narrative Review.运动对新冠病毒肺炎患者的影响：一项叙述性综述
Med J Islam Repub Iran. 2022 Sep 10;36:104. doi: 10.47176/mjiri.36.104. eCollection 2022.

本文引用的文献

1
Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.法匹拉韦在两名新冠肺炎患者中引起肾毒性。
J Assoc Physicians India. 2021 Jan;69(1):90.
2
Prevalence, Clinical Manifestations, and Biochemical Data of Hypertensive versus Normotensive Symptomatic Patients with COVID-19: A Comparative Study.高血压与血压正常的 COVID-19 有症状患者的患病率、临床表现和生化数据：一项比较研究。
Acta Biomed. 2020 Nov 10;91(4):e2020164. doi: 10.23750/abm.v91i4.10540.
3
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
COVID-19 药物再利用时肾功能和肝功能损伤患者的剂量推荐。
Drugs R D. 2021 Mar;21(1):9-27. doi: 10.1007/s40268-020-00333-0. Epub 2020 Dec 17.
4
Role of favipiravir in the treatment of COVID-19.法匹拉韦在治疗 COVID-19 中的作用。
Int J Infect Dis. 2021 Jan;102:501-508. doi: 10.1016/j.ijid.2020.10.069. Epub 2020 Oct 30.
5
COVID-19 and the kidney.新型冠状病毒肺炎与肾脏。
Cleve Clin J Med. 2020 Oct 1;87(10):619-631. doi: 10.3949/ccjm.87a.20072.
6
Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.在维持性血液透析的终末期肾病患者中使用法匹拉韦治疗新型冠状病毒病 2019 的疗效。
CEN Case Rep. 2021 Feb;10(1):126-131. doi: 10.1007/s13730-020-00534-1. Epub 2020 Sep 17.
7
Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study.2型糖尿病与非糖尿病COVID-19症状性患者的患病率、临床表现及生化数据：一项对比研究。
Acta Biomed. 2020 Sep 7;91(3):e2020010. doi: 10.23750/abm.v91i3.10214.
8
Acute kidney injury in patients hospitalized with COVID-19.COVID-19 住院患者中的急性肾损伤。
Kidney Int. 2020 Jul;98(1):209-218. doi: 10.1016/j.kint.2020.05.006. Epub 2020 May 16.
9
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
10
Drug-induced nephrotoxicity.药物性肾毒性
Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s82-s90. doi: 10.1590/1806-9282.66.S1.82.